AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook

AtriCure, Inc.

2025-Q2 EPS reported -$0.27 revenue$259,759,000

Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).
Net loss $6.2M, improved $1.8M YoY; adjusted EBITDA $15.4M, up $7.6M YoY.
Basic/diluted EPS loss $0.13 vs $0.17; adjusted EPS loss $0.02 vs $0.17.
Completed enrollment of 6,500 patients in the LeAAPS trial.
Company raised full-year 2025 financial outlook.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.